Donny Wynn, MD
Endocrinology, Diabetes & Metabolism · Oklahoma City, OKNPI 1942341573
Payments from drug & device makers
Across 519 payments — averaging $21.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$992
- Dexcom, Inc.$855
- Lilly USA, LLC$850
- Xeris Pharmaceuticals, Inc.$794
- Abiomed$670
- Amgen$626
- plus $6K from 31 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 41 | $992 |
| Dexcom, Inc. | 43 | $855 |
| Lilly USA, LLC | 49 | $850 |
| Xeris Pharmaceuticals, Inc. | 42 | $794 |
| Abiomed | 5 | $670 |
| Amgen(2 entities) | 31 | $626 |
| Bayer | 45 | $574 |
| Novo Nordisk | 32 | $496 |
| Sanofi-aventis U.S. LLC | 22 | $451 |
| Boehringer Ingelheim | 24 | $412 |
| Tandem Diabetes Care, Inc. | 17 | $399 |
| Abbott | 19 | $384 |
| AbbVie(2 entities) | 17 | $334 |
| Insulet Corporation | 15 | $332 |
| Ascensia Diabetes Care US Inc. | 7 | $286 |
| Medtronic | 4 | $257 |
| IBSA Pharma Inc. | 11 | $235 |
| Recordati_rare_diseases_inc. | 10 | $218 |
| BETA Bionics, Inc. | 10 | $184 |
| Sequel Med Tech, LLC | 10 | $181 |
| Chiesi USA, Inc. | 7 | $161 |
| Mannkind Corporation | 8 | $152 |
| Echosens North America, Inc. | 1 | $125 |
| Radius Health, Inc. | 5 | $122 |
| Cequr Corporation | 3 | $120 |
| Ascendis Pharma Endocrinology Inc | 5 | $118 |
| Antares Pharma, Inc. | 6 | $101 |
| Nevro Corp. | 4 | $94 |
| Novartis | 5 | $92 |
| AstraZeneca(2 entities) | 4 | $89 |
| Neurocrine Biosciences, Inc. | 3 | $75 |
| Kyowa Kirin, Inc. | 3 | $69 |
| Astellas Pharma US Inc | 4 | $62 |
| Amneal Pharmaceuticals LLC | 2 | $39 |
| Pfizer | 2 | $35 |
| Lifescan, Inc. | 2 | $35 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
How this compares
$11,041 in reported general payments places this provider in the 75th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
See all endocrinology, diabetes & metabolism providers in Oklahoma →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Oklahoma City
- Robert ScofieldOklahoma City$189K
- Jonea LimOklahoma City$172K
- Christian MangrumOklahoma City$54K
- Cheryl BlackOklahoma City$8K
- Diana KennedyOklahoma City$8K
- Ali TipuOklahoma City$8K
- Amanda LagrecaOklahoma City$7K
- Bassam ArodakOklahoma City$6K
- Myrto EliadesOklahoma City$5K
- Hamsa AljumailiOklahoma City$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.